RedHill Biopharma Ltd. · NASDAQ:RDHL
RedHill Biopharma — Investor Presentation (September 2021)
71 slides from RedHill Biopharma's investor presentation, September 2021
Slide 1: RedHill Biopharma Ltd. Corporate Presentation
RedHill Biopharma Ltd. (“RDHL”) Corporate Presentation September 2021
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company’s securities or to participate in any investment in the Company. No representation or warranty is made to the accura
Slide 3: Corporate Highlights
Corporate Highlights An emerging U.S. specialty biopharmaceutical company (Nasdaq: RDHL), primarily focused on U.S. commercialization and development of drugs for gastrointestinal (GI) diseases and infectious diseases Strong U.S. Commercial Footprint and Robust Development Pipeline with Multiple Nea
Slide 4: Emerging U.S. Specialty Pharma: Select Programs
Emerging U.S. Specialty Pharma: Select Programsi Commercial Productsii Talicia® (omeprazole magnesium, amoxicillin and rifabutin) - H. pylori infection in adults iii Movantik® (naloxegol) - Opioid induced constipation (OIC) in adults with chronic non-cancer pain Aemcolo® (rifamycin) - Travelers’ dia
Slide 5: Emerging U.S. Specialty Pharma
Emerging U.S. Specialty Pharmai A leading U.S. specialty pharmaceutical company ii Opaganib GI RHB-107 Oncology/GI RHB-104 Crohn’s disease Opaganib Cholangiocarcinoma RHB-204 NTM RHB-106 Bowel preparation Opaganib COVID-19 RHB-102 Gastroenteritis RHB-107 COVID-19 RHB-102 IBS-D Sales force of ~100 re
Slide 6: Financial Highlights
Financial Highlightsi RedHill Biopharma Ltd. Nasdaq: RDHL Market Cap (approx.) $443 million American Depositary Shares (ADSs) 46.7 million (Representing 466.7 million ordinary shares outstanding) Cash Balance as of June 30, 2021ii Approx. $71.5 million i Financial information as of September 3, 2021
Slide 7: Revenue Growth Despite Challenging Pandemic Conditions
Revenue Growth Despite Challenging Pandemic Conditions RedHill Quarterly Net Revenue 25 20 15 Million USD 10 5 0 Q2/2020 Q3/2020 Q4/2020 Q1/2021 Q2/2021 7
Slide 8: Highly Experienced Senior Leadership
Highly Experienced Senior Leadership Dror Ben-Asher, Chief Executive Officer Gilead Raday, Chief Operating Officer P.C.M.I. Ltd. MSc Neurology, MBE Cambridge, Sepal Pharma Adi Frish, Chief Corporate & Business Development Officer Guy Goldberg, Chief Business Officer Y. Ben-Dror, MediGus Eagle Pharma
Slide 9: Board of Directors and Advisory Board
Board of Directors and Advisory Board Board of Directors Dror Ben-Asher, CEO Rick D. Scruggs P.C.M.I. Ltd. Salix, Watson, Oclassen Eric Swenden Ofer Tsimchi Alterphama nv, Lifeline Scientific Danbar, Polysack, Director in several companies Kenneth Reed, MD Alla Felder Dermatologist; Director Minerva
Slide 10: Commercial Operations - Strong U.S. Presence
Commercial Operations - Strong U.S. Presence Launched Aemcolo® in Q4/2019, Talicia® in Q1/20 and promoting Movantik® since April 2020 U.S. Commercial Headquarters (Raleigh, NC) Marketing Managed markets Market access Supply chain Medical affairs Compliance Sales force of 100 reps + 30 field support
Slide 11: Movantik indicated for opioid-induced constipation
Indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain I Movantik® is a registered trademark of AstraZeneca 11
Slide 12: MOVANTIK Important Safety Information
MOVANTIK® (naloxegol) Important Safety Information IMPORTANT SAFETY INFORMATION • MOVANTIK may cause serious side effects, including: – Opioid withdrawal. You may have symptoms of opioid withdrawal during treatment with MOVANTIK, including sweating, chills, diarrhea, stomach pain, anxiety, irritabil
Slide 13: Movantik - FDA-Approved for Treatment of Opioid-Induced Constipation
Movantik®- FDA-Approved for Treatment of Opioid-Induced Constipation Approved Treatment of opioid-induced constipation (OIC) in adults with chronic non- Indication cancer pain Drug Oral naloxegol tablets available in 12.5mg and 25mg dosage strengths Approved in the U.S. in 2014 - launched in 2015 by
Slide 14: OIC is a Large and Underserved Market
OIC is a Large and Underserved Marketi 6.2 – 12.4ii million 71% of patients with OIC opioid users in the report little to no benefit U.S. may have OICi from constipation treatmentsiii 15 million U.S. patients with chronic pain are prescribed opioidsiii 50 million U.S. adults with chronic painiv i Be
Slide 15: Constipation is One of the Most Common Side Effects of Opioid Therapy
Constipation is One of the Most Common Side Effects of Opioid Therapyi Results from a meta-analysis that included randomized controlled trials of opioid therapy in patients with chronic non-cancer pain:ii 60% 50% Frequency (%) 41% 40% 32% 29% 30% Opioids 20% Placebo 20% 15% 15% 10% 12% 11% 10% 7% 7%
Slide 16: Movantik is a Once-Daily Oral Therapy Specifically Designed to Treat OIC
Movantik® is a Once-Daily Oral Therapy Specifically Designed to Treat OIC Movantik functions as a peripherally acting mu-opioid receptor antagonist (PAMORA) in tissues such as the bowel, thereby decreasing the constipating effect of opioids while limiting the potential for interference with centrall
Slide 17: Movantik - the #1 Prescribed Oral PAMORA
Movantik - the #1 Prescribed Oral PAMORAi Over 2,000,000 prescriptions written since 2015ii The #1 prescribed oral PAMORA specifically designed to treat OICii The American Gastroenterological Association recommends the use of Movantik as one of the prescription options for management of OICiii Movan
Slide 18: Movantik Acquisition - A Transformative Event for RedHill
Movantik Acquisition - A Transformative Event for RedHill RedHill acquired the global rights to Movantiki (excluding Europe and Canada) from AstraZeneca in April 2020 • RedHill benefits from the large investment made by AstraZeneca to make Movantik a brand leader − First oral PAMORA approved in the
Slide 19: Continued Best Coverage in PAMORA Class
Continued Best Coverage in PAMORA Class Movantik Lives Covered 90% ✓ Best coverage without restrictions in 80% 9 out of 9 out of the PAMORA class for both 70% 10 lives 10 lives Commercial and Government 60% segments 50% 40% ✓ Improved both Commercial and 30% Medicare Part D coverage since 20% acquir
Slide 20: Talicia indicated for H. pylori infection
Indicated for the treatment of Helicobacter pylori infection in adults Approved for Marketing by U.S. FDA Following Two Positive Phase 3 Studies Launched in the U.S. 20
Slide 21: Talicia Important Safety Information
Talicia® (omeprazole magnesium, amoxicillin and rifabutin) Important Safety Information Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity t
Slide 22: Talicia - Approved by U.S. FDA for Treatment of H. pylori Infection
Talicia®- Approved by U.S. FDA for Treatment of H. pylori Infection in Adults Approved Treatment of H. pylori infection in adults Indication Omeprazole magnesium, amoxicillin and rifabutin 10 mgi/ 250 mg/ 12.5 mg Drug delayed-release capsulesi Approved NDA approved by U.S. FDA in November 2019 - lau
Slide 23: Talicia Field Promotion Initiated July 2020
Talicia Field Promotion Initiated July 2020 RedHill’s U.S. sales force promoting Talicia® to approx. 25,000 gastroenterologists, primary care physicians and other healthcare providers Rapid expansion in managed care coverage since launch 23
Slide 24: Talicia Delivered >10% Growth in Q2/21
Talicia Delivered >10% Growth in Q2/21 Talicia nTRx Growth 1,600 1,400 Month 6 1,200 Planned Field Starts Launch Returning 1,000 nTRx Volume “Full” 800 Strength 600 400 COVID-19 Pullback 200 - Talicia continues to achieve launch milestones with over 10% Q/Q growth in Q2/21 and strong commercial cove
Slide 25: Talicia Commercial Coverage Continues to Improve
Talicia Commercial Coverage Continues to Improve and Now Covers 8 out of 10 lives ✓ Talicia Commercial coverage Talicia Lives Covered continues to grow; Majority of 80% Commercially insured patients 70% 8 out of can now access Talicia with 60% 10 lives 6 out of no restrictions 50% 10 lives 40% ✓ 8 o
Slide 26: H. pylori - Increasing Global Disease
H. pylori - Increasing Global Disease H. pylori infection → Progressive gastro-duodenal damage • H. pylori - a Group I carcinogen and the strongest risk factor for gastric canceri and peptic ulcer disease; Also associated with iron deficiency, B12 deficiency and drug malabsorption - Gastric cancer -
Slide 27: H. pylori Resistance - An Important Public Health Concern
H. pylori Resistance - An Important Public Health Concern WHO: H. pylori ranked as pathogen with FDA: H. pylori identified under the GAIN Act as “high priority” need for new treatments pathogen posing serious threat to public health • February 2017 - WHO Enterococcus faecium, • Talicia® received FDA
Slide 28: Positive Pivotal Phase 3 Study
Positive Pivotal Phase 3 Study Randomized, Double-Blind, Active Comparator, Two-Arm, Pivotal Phase 3 Study (ERADICATE Hp2), Comparing Talicia® Against a Regimen of Amoxicillin and Omeprazole Alone in the Treatment of Confirmed H. pylori Infection in Dyspepsia Patients, Regardless of Ulcer Status Num
Slide 29: Positive Pivotal Phase 3 Study Results
Positive Pivotal Phase 3 Study The ERADICATE Hp2 study met its primary endpoint with a high degree of statistical significance (p<0.0001) p<0.0001 • Top-line results demonstrated 84% eradication 90% 84% of H. pylori with Talicia® vs. 58% in the active comparator arm (p<0.0001) (ITT) 80% • 90% eradic
Slide 30: Resistance Patterns in Pivotal Study Show Negligible Resistance
Resistance Patterns in Pivotal Study Demonstrate Zero to Negligible Resistance For Component Antibiotics in Talicia® H. pylori Resistance to Standard-of-Care • H. pylori culture results from patients across 20 U.S. states supported the high resistance of H. pylori to the antibiotics most commonly us
Slide 31: Positive First Phase 3 Study
Positive First Phase 3 Study A Randomized Placebo-Controlled Phase 3 Study (ERADICATE Hp) to Assess the Safety and Efficacy of Talicia® in the Treatment of Confirmed H. pylori Infection in Dyspepsia Patients, Regardless of Ulcer Status Number of Subjects 118 in the U.S. Treatment Duration 14 days -
Slide 32: Strong Protection from Competition and Substitution
Strong Protection from Competition and Substitution • FDA QIDP designation providing eligibility for a total of 8 years of market exclusivity • Talicia is covered by U.S. patents covering the unique ‘all-in-one’ capsule formulation and distinct PK profile, extending until at least 2034, with additio
Slide 33: Talicia - Clear Clinical Differentiation, Large Market Opportunity
Talicia®- Clear Clinical Differentiation Provides Large Potential for Market Opportunity in the U.S. and WW High Prevalence of Diminished Efficacy Current Brand $4.8B Global Market H. pylori of Standard-of-Care - Medications Lack Approx. 60% Clinical Differentiation Over 27M treatments annually WWi:
Slide 34: Aemcolo indicated for travelers' diarrhea
Indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of E. coli in adults Approved for Marketing by U.S. FDA Launched in the U.S. by RedHill - December 2019 34
Slide 35: Aemcolo Important Safety Information
Aemcolo® (rifamycin) - Important Safety Information INDICATION AND IMPORTANT SAFETY INFORMATION Aemcolo® is indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli (E. coli) in adults. Limitations of Use Aemcolo® is not indicated in patients with diarrhea
Slide 36: Aemcolo Launched by RedHill in the U.S.
Launched by RedHill in the U.S. - December 2019 • A rifamycin antibacterial approved by U.S. FDA in Nov. 2018 for the treatment of travelers’ diarrhea caused by noninvasive strains of E. coli in adults • In-licensed U.S. rights from Cosmo Pharmaceuticals N.V. in Oct. 2019 • Robust U.S. patent portfo
Slide 37: High Travel Spending Points to Significant Commercial Opportunity
High Travel Spending Per Person in the U.S. Points to Significant Commercial Opportunity Travelers’ diarrhea is a significant market: • Approximately 93 million Americans travel abroad in 2018, of which 60 million traveled to medium to high risk regionsi • Travelers’ diarrhea may affect up to 70% of
Slide 38: Opaganib (ABC294640)
Opaganib (ABC294640)i Investigational new drug First-in-class, orally-administered sphingosine kinase-2 (SK2) inhibitor targeting multiple oncology, inflammatory and GI indications Top-line results from global Phase 2/3 study upcoming for COVID-19; Positive top-line data from U.S. Phase 2 study for
Slide 39: Opaganib - SK2 Inhibitor for COVID-19, Oncology, GI and Inflammatory Diseases
Opaganib - SK2 Inhibitor for COVID-19 and Oncology, Gastrointestinal and Inflammatory Diseases - Potential first-in-class, orally-administered sphingosine kinase-2 (SK2) inhibitor - with anti-cancer, anti-inflammatory activities, targeting multiple oncology, The Product inflammatory and GI indicatio
Slide 40: Opaganib - Complete Inhibition of SARS-CoV-2
Opaganib - Complete Inhibition of SARS-CoV-2 Opaganib’s unique MoA combines potent antiviral and anti-inflammatory activities, targeting a host cell component and minimizing likelihood of resistance Potent Anti-SARS-CoV-2 Activity: Opaganib evaluated in in vitro model of human lung bronchial tissue
Slide 41: Opaganib - COVID-19 Studies
Opaganib - COVID-19 Studies Global Phase 2/3 Study - U.S. Phase 2 Study - Last Patient Out Announced July 19, 2021 Positive data announced Randomized, double-blind, parallel-arm, U.S. randomized, double-blind, placebo- placebo-controlled global Phase 2/3 study controlled Phase 2 study • 475 subjects
Slide 42: Opaganib Phase 2 COVID-19 Study - Positive Top-Line Data
Opaganib Phase 2 COVID-19 Study - Positive Top-Line Data U.S. Phase 2 study of opaganib in patients hospitalized with COVID-19 pneumonia: Non-powered study of 40 patients, randomized 1:1 to received opaganib or placebo on top of standard-of-care. Follow up for up to 42 days post treatment initiation
Slide 43: Opaganib - Novel SK2 Inhibitor
Opaganib - Novel SK2 Inhibitor with Anti-Cancer, Anti- Inflammatory and Anti-Viral Activities Opaganib selectively inhibits SK2, a lipid kinase with multiple cellular functions - potentially inhibiting tumor growth, pathological inflammation, and viral replication Opaganib • Sphingosine kinase-2 (SK
Slide 44: Opaganib - Positive Phase 1 Study
Opaganib - Positive Phase 1 Study Phase 1 Clinical study of opaganib in Patients with Advanced Solid Tumors Study - Open-label, dose-escalation, PK and PD, first-in-human Phase I study with opaganib Design Site - Medical University of South Carolina Subjects - 21 patients with advanced solid tumors,
Slide 45: Opaganib - Phase 2a Study for Cholangiocarcinoma Ongoing
Opaganib - Phase 2a Study for Cholangiocarcinoma Ongoing Single-arm Phase 2a clinical study evaluating opaganib in patients with advanced, unresectable, intra-hepatic, perihilar and extra-hepatic cholangiocarcinoma Sites Mayo Clinic, MD Anderson, Huntsman Cancer Institute, Emory University Initiated
Slide 46: RHB-107 (upamostat)
RHB-107 (upamostat) Investigational new drug Potential first-in-class small molecule targeting oncology, inflammatory lung diseases and GI indications U.S. Phase 2/3 COVID-19 ongoing in non-hospitalized patients 46 46
Slide 47: RHB-107 - S1 Serine Protease Inhibitor
RHB-107 - S1 Serine Protease Inhibitor with Ongoing Phase 2/3 COVID-19 Study in Non-Hospitalized Patients Potential first-in-class, orally-administered inhibitor of S1 family of trypsin-like serine proteases with potential for use in the treatment of cancer, inflammatory lung diseases, irritable bow
Slide 48: RHB-107 - Ongoing Phase 2/3 COVID-19 Study
RHB-107 - Ongoing Phase 2/3 COVID-19 Study Ongoing U.S. Phase 2/3 study with RHB-107 in non-hospitalized patients with symptomatic COVID-19 not requiring supplemental oxygen ✓ Study design: 310 patients to be enrolled in a 2-part, multicenter, randomized, double-blind, placebo-controlled, parallel-g
Slide 49: RHB-204
RHB-204 Investigational new drug Targeting pulmonary nontuberculous Mycobacteria (NTM) disease - with QIDP designation, including Fast-Track development status U.S. Phase 3 Study Ongoing 49
Slide 50: RHB-204 - Targeting First-Line Pulmonary NTM Disease
RHB-204 - Targeting First-Line Pulmonary NTM Disease Planned - Pulmonary Mycobacterium avium Complex (MAC) disease in adults with Indication nodular bronchiectasis - Patent-protected, oral all-in-one combination of three antibiotic drugs The Product (clarithromycin, clofazimine and rifabutin) each k
Slide 51: RHB-204 for Pulmonary NTM - Background and Epidemiology
RHB-204 for Pulmonary NTM - Background and Epidemiology • Difficult to treat infection with no FDA-approved first-line standard-of-care • NTM are a ubiquitous bacteria, mostly non-pathogenic but can cause human diseasei • Pulmonary manifestations account for 80-90% of NTM associated diseaseii • Appr
Slide 52: RHB-204 - CleaR-MAC Phase 3 Study Ongoing
RHB-204 - CleaR-MAC Phase 3 Study Ongoing A Phase 3 study to assess RHB-204 as a first-line treatment for the Treatment of pulmonary Mycobacterium avium Complex (MAC) disease in adults with nodular bronchiectasis Study Initiated - November 2020 - Multi-center, randomized, double-blind, two-part, pla
Slide 53: RHB-104
RHB-104 Investigational new drug Combination therapy targeting MAP bacteria for treatment of Crohn’s disease and potentially other autoimmune diseases Positive First Phase 3 Study in Crohn’s Disease - Study Successfully Met Its Primary Endpoint and Key Secondary Endpoints 53
Slide 54: The Link between Crohn's Disease and MAP
The Link between Crohn’s Disease and MAP Growing evidence that intracellular mycobacteria play a crucial role in Crohn’s disease • MAP (mycobacterium avium subsp. paratuberculosis) is the causative agent of Johne’s disease, an infectious disease in cattle, clinically and pathologically similar to Cr
Slide 55: RHB-104 for Crohn's - Product and Market Overview
RHB-104 for Crohn’s - Product and Market Overview Planned Treatment of Crohn’s disease in adult patients Indication Patent-protected combination of 3 antibiotics (clarithromycin, clofazimine and The product rifabutin) in a single oral capsule with potent intracellular, antimycobacterial and anti-inf
Slide 56: RHB-104 Positive First Phase 3 Study in Crohn's
RHB-104 Positive First Phase 3 Study in Crohn’s - Met Primary Endpoint and Key Secondary Endpoints Multi-center, randomized, double-blind, placebo-controlled, parallel group study (MAP US study) to assess efficacy and safety of orally-administered, fixed-dose combination RHB-104 in subjects with mod
Slide 57: RHB-104 Crohn's Disease Phase 3 - Positive Results
RHB-104 Crohn’s Disease Phase 3 - Positive Results The MAP US Phase 3 study met its primary and key secondary endpoints, demonstrating meaningful, consistent and statistically significant clinical activity of orally-administered RHB-104 as an add-on to standard-of-care treatments RHB-104 (n= 166) Pl
Slide 58: RHB-104 Crohn's Disease Phase 3 - Positive Results
RHB-104 Crohn’s Disease Phase 3 - Positive Results Additional Endpoints Met: ✓ Durable remission weeks 16-52: statistically significant benefit in durable remission on all visits, weeks 16-52, demonstrating an improvement of 100% over placebo ✓ Maintenance of remission: analysis of maintenance of re
Slide 59: RHB-104 Crohn's Disease Phase 3 - Positive Results
RHB-104 Crohn’s Disease Phase 3 - Positive Results Effects of concomitant immunomodulators and corticosteroids: Remission at week 26 concomitant meds subgroup analyses demonstrated the impact of RHB-104 as an add-on therapy to a variety of standard-of-care agents despite not being prospectively powe
Slide 60: RHB-104 Crohn's Disease Phase 3 - Endoscopic Response
RHB-104 Crohn’s Disease Phase 3 - Positive Results Endoscopic response: ✓ Endoscopy was voluntary in the study ✓ In a small subset of patients (n=35) in whom endoscopy was performed, results showed meaningful improvement in endoscopic healing (Simple Endoscopic Score for Crohn's Disease (SES-CD)) at
Slide 61: RHB-104 - Median Fecal Calprotectin
RHB-104 Crohn’s Disease Phase 3 - Positive Results Median Fecal Calprotectin ✓ Marked and continuous decline of calprotectin inflammatory marker in the RHB-104 active arm from baseline through week 52 RHB-104 Placebo 400 346.5 355.4 350 333.6 314 300 ∆143 276.5 ∆211 250 ∆115 Median 200 189.8 161.1 1
Slide 62: RHB-104 - % High Fecal Calprotectin
RHB-104 Crohn’s Disease Phase 3 - Positive Results % High Fecal Calprotectin** ✓ Proportion of high calprotectin declined significantly in the RHB-104 active arm from baseline through week 52 (weeks 12, 26 and 52) RHB-104 Placebo P*=0.0001 P*=0.0017 P*=0.0026 90 80 77.9 72.9 72.6 69.9 67.5 70 ∆25.2%
Slide 63: RHB-104 - Multiple Barriers to Entry
RHB-104 - Multiple Barriers to Entry • Robust global patent portfolio covering RHB-104, with additional claims being pursued • Potential 3 years exclusivity for treatment of Crohn’s disease • Limited availability of clofazimine (distributed by the World Health Organization (WHO) and Novartis) and ge
Slide 64: RHB-102
RHB-102i Investigational new drug A bi-modal extended release, once-daily, ondansetron RHB-102 24 mg - Positive Results from a U.S. Phase 3 Study for Gastroenteritis/Gastritis - Met Primary Endpoint RHB-102 12 mg - Positive Results from a U.S. Phase 2 Study for IBS-D Met Primary Endpoint i Bekinda®
Slide 65: RHB-102 24 mg: Gastroenteritis & Gastritis - Positive First Phase 3 Results
RHB-102 24 mg: Gastroenteritis & Gastritis - Positive First Phase 3 Results A Randomized, Double-Blind, Placebo Controlled, Parallel Group Phase 3 Study (GUARD study) to Assess the Safety and Efficacy of RHB-102i 24 mg for the Treatment of Acute Gastroenteritis & Gastritis The Product Patent-protect
Slide 66: RHB-102 24 mg: Gastroenteritis & Gastritis Positive Phase 3 Results
RHB-102 24 mg: Gastroenteritis & Gastritis Positive Phase 3 Results A Randomized, Double-Blind, Placebo Controlled, Parallel Group Phase 3 Study (“GUARD”) to Assess Safety and Efficacy of RHB-102 24 mg for Treatment of Acute Gastroenteritis & Gastritis - The Phase 3 GUARD study successfully met its
Slide 67: RHB-102 12 mg: IBS-D Positive Phase 2 Results
RHB-102 12 mg: IBS-D Positive Phase 2 Results A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel Group Phase 2 Clinical Study Designed to Evaluate the Safety and Efficacy of RHB-102 12 mg in Patients Suffering from Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) The Product Patent-
Slide 68: RHB-102 12 mg: IBS-D Positive Phase 2 Results
RHB-102 12 mg: IBS-D Positive Phase 2 Results A Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel Group Phase 2 Clinical Study Designed to Evaluate the Safety and Efficacy of RHB-102 12 mg in Patients Suffering from Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) - Primary endpoint:
Slide 69: RHB-106
RHB-106 Investigational new drug Proprietary Encapsulated Formulation for Bowel Preparation 69 69
Slide 70: RHB-106 - Encapsulated Bowel Preparation
RHB-106 - Encapsulated Bowel Preparation Preparation of the gastrointestinal tract prior to abdominal Planned Indication procedures/surgeries, such as colonoscopy − Proprietary, flavorless, odorless, solid oral encapsulated formulation for bowel preparation The Product − Caplet formulation composed
Slide 71: Thank You!
Thank You! RedHill Biopharma Ltd. 21 Ha’arba’a St. Tel-Aviv, 6473921, Israel Website: www.RedHillbio.com Email: [email protected] 71 Tel: +972-3-541-3131
RedHill Biopharma — Investor Presentation (September 2021) on 6ix